N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs
Aim. To determine N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with early rheumatoid arthritis (RA) before the use of disease-modifying antirheumatic drugs (DMARDs); to compare NT-proBNP values with traditional risk factors (TRF), cardiovascular diseases (CVD), inflammator...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2016-05-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/31963/pdf |
| _version_ | 1818129494414721024 |
|---|---|
| author | I G Kirillova D S Novikova T V Popkova E N Aleksandrova A A Novikov Yu N Gorbunova E I Markelova Yu O Korsakova S I Glukhova A V Volkov E L Luchikhina N V Demidova K A Kasumova S A Vladimirov M A Kanonirova G L Lukina D E Karateev E L Nasonov |
| author_facet | I G Kirillova D S Novikova T V Popkova E N Aleksandrova A A Novikov Yu N Gorbunova E I Markelova Yu O Korsakova S I Glukhova A V Volkov E L Luchikhina N V Demidova K A Kasumova S A Vladimirov M A Kanonirova G L Lukina D E Karateev E L Nasonov |
| author_sort | I G Kirillova |
| collection | DOAJ |
| description | Aim. To determine N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with early rheumatoid arthritis (RA) before the use of disease-modifying antirheumatic drugs (DMARDs); to compare NT-proBNP values with traditional risk factors (TRF), cardiovascular diseases (CVD), inflammatory markers, and left ventricular (LV) diastolic dysfunction (DD). Subjects and methods. The investigation enrolled 74 patients with a valid RA diagnosis (the 2010 ACR/EULAR criteria), 56 (74%) women, median (Me) age, 54 years; disease duration, 7 months; seropositive for IgM rheumatoid factor (87%) and/or anti-cyclic citrullinated peptide antibodies (100%) with no history of the use of DMARDs and glucocorticosteroids. Duplex scanning and echographic findings were used to assess TRF for CVD and carotid artery atherosclerosis (CAA) in all the patients with early RA prior to therapy. An E/A ratio was used as a criterion for LVDD. Results. NT-proBNP concentrations in patients with early RA proved to be higher than those in the control group (p |
| first_indexed | 2024-12-11T07:50:02Z |
| format | Article |
| id | doaj.art-f7c1e68a78364be78a49b432ab41d573 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-11T07:50:02Z |
| publishDate | 2016-05-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-f7c1e68a78364be78a49b432ab41d5732022-12-22T01:15:22Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422016-05-01885192628979N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugsI G KirillovaD S NovikovaT V PopkovaE N AleksandrovaA A NovikovYu N GorbunovaE I MarkelovaYu O KorsakovaS I GlukhovaA V VolkovE L LuchikhinaN V DemidovaK A KasumovaS A VladimirovM A KanonirovaG L LukinaD E KarateevE L NasonovAim. To determine N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with early rheumatoid arthritis (RA) before the use of disease-modifying antirheumatic drugs (DMARDs); to compare NT-proBNP values with traditional risk factors (TRF), cardiovascular diseases (CVD), inflammatory markers, and left ventricular (LV) diastolic dysfunction (DD). Subjects and methods. The investigation enrolled 74 patients with a valid RA diagnosis (the 2010 ACR/EULAR criteria), 56 (74%) women, median (Me) age, 54 years; disease duration, 7 months; seropositive for IgM rheumatoid factor (87%) and/or anti-cyclic citrullinated peptide antibodies (100%) with no history of the use of DMARDs and glucocorticosteroids. Duplex scanning and echographic findings were used to assess TRF for CVD and carotid artery atherosclerosis (CAA) in all the patients with early RA prior to therapy. An E/A ratio was used as a criterion for LVDD. Results. NT-proBNP concentrations in patients with early RA proved to be higher than those in the control group (phttps://ter-arkhiv.ru/0040-3660/article/viewFile/31963/pdfearly rheumatoid arthritisremarcant-probnpdiastolic dysfunctioncardiovascular risknt-probnp |
| spellingShingle | I G Kirillova D S Novikova T V Popkova E N Aleksandrova A A Novikov Yu N Gorbunova E I Markelova Yu O Korsakova S I Glukhova A V Volkov E L Luchikhina N V Demidova K A Kasumova S A Vladimirov M A Kanonirova G L Lukina D E Karateev E L Nasonov N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs Терапевтический архив early rheumatoid arthritis remarca nt-probnp diastolic dysfunction cardiovascular risk nt-probnp |
| title | N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs |
| title_full | N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs |
| title_fullStr | N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs |
| title_full_unstemmed | N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs |
| title_short | N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs |
| title_sort | n terminal pro brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease modifying antirheumatic drugs |
| topic | early rheumatoid arthritis remarca nt-probnp diastolic dysfunction cardiovascular risk nt-probnp |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/31963/pdf |
| work_keys_str_mv | AT igkirillova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT dsnovikova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT tvpopkova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT enaleksandrova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT aanovikov nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT yungorbunova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT eimarkelova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT yuokorsakova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT siglukhova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT avvolkov nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT elluchikhina nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT nvdemidova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT kakasumova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT savladimirov nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT makanonirova nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT gllukina nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT dekarateev nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs AT elnasonov nterminalprobrainnatriureticpeptidelevelsanddiastolicdysfunctioninpatientswithearlyrheumatoidarthritisbeforetheadministrationofdiseasemodifyingantirheumaticdrugs |